Matteo Lambertini: Major benefit of adjuvant olaparib for BRCA carriers with high-risk early Breast Cancer
Matteo Lambertini shared on X:
“Presented at SABCS24 updated data from the olympiA trial showing major benefit of adjuvant olaparib for BRCA carriers with high-risk early Breast Cancer.”
Matteo Lambertini is an adjunct professor and consultant in medical oncology at the IRCCS Policlinico San Martino Hospital and the University of Genova in Italy. He specializes in managing breast cancer in young women, particularly addressing fertility and pregnancy-related issues post-diagnosis.
Lambertini’s notable research includes using GnRH agonists during chemotherapy to preserve ovarian function and studying the safety of pregnancy after breast cancer. He also serves on the scientific boards of ESMO, ESHRE, and AIOM for fertility preservation in cancer patients.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023